AR068488A1 - Sales de adicion de compuestos inhibidores de la enzima de conversion de angiotensina con acidos donadores de no, su procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la hipertension y otras enfermedades cardiovasculares. - Google Patents

Sales de adicion de compuestos inhibidores de la enzima de conversion de angiotensina con acidos donadores de no, su procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la hipertension y otras enfermedades cardiovasculares.

Info

Publication number
AR068488A1
AR068488A1 ARP080104074A ARP080104074A AR068488A1 AR 068488 A1 AR068488 A1 AR 068488A1 AR P080104074 A ARP080104074 A AR P080104074A AR P080104074 A ARP080104074 A AR P080104074A AR 068488 A1 AR068488 A1 AR 068488A1
Authority
AR
Argentina
Prior art keywords
branched
linear
alkyl
alkyl group
formula
Prior art date
Application number
ARP080104074A
Other languages
English (en)
Inventor
Philippe Gloanec
Jean-Gilles Parmentier
Guillaume De Nanteuil
Bernard Portevin
Alain Rupin
Alain Benoist
Tony Verbeuren
Serge Simonet
Christine Courchay
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39539691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR068488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR068488A1 publication Critical patent/AR068488A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/36One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/081,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Reivindicacion 1: Compuestos de formula (1) (A)m À (B)n en la que A representa un compuesto inhibidor de la enzima de conversion de la angiotensina que conlleva al menos una funcion básica salificable, B representa un compuesto que conlleva al menos una funcion ácida salificable y al menos un grupo donador de NO, m representa el numero de funciones salificadas de B y n representa el numero de funciones básica salificadas de A, debiendo entenderse que el o los enlaces entre A y B son de tipo ionico. Reivindicacion 2: Compuestos de formula (1) segun la reivindicacion 1, en la que A pertenece a la formula (2) en la que: R1 representa un átomo de hidrogeno o un grupo alquilo C1-6 lineal o ramificado, R2 representa un grupo alquilo C1-6 lineal o ramificado o aril alquilo C1-6 en el que el grupo alquilo es lineal o ramificado, R3 representa un grupo alquilo C1-6 lineal o ramificado o alquil C1-6amino en el que el grupo alquilo es lineal o ramificado, el resto de formula (3) representa un sistema mono- o bicíclico nitrogenado que tiene 3 a 12 átomos de carbono y pudiendo tener uno o varios heteroátomos suplementarios seleccionados entre N, O y S, estando dicho sistema opcionalmente sustituido por uno o varios grupos seleccionados entre alquilo C1-6 lineal o ramificado, alcoxi C1-6 lineal o ramificado, oxo, carboxi, arilo, cicloalquilo C3-8, heteroarilo, carboxi-alquilo C1-6 en el que el grupo alquilo es lineal o ramificado, hidroxi, debiendo entenderse que cuando el sistema nitrogenado es bicíclico, puede estar fisionado, espiránico o puenteado.
ARP080104074A 2007-09-21 2008-09-19 Sales de adicion de compuestos inhibidores de la enzima de conversion de angiotensina con acidos donadores de no, su procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la hipertension y otras enfermedades cardiovasculares. AR068488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706629A FR2921365B1 (fr) 2007-09-21 2007-09-21 Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
AR068488A1 true AR068488A1 (es) 2009-11-18

Family

ID=39539691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104074A AR068488A1 (es) 2007-09-21 2008-09-19 Sales de adicion de compuestos inhibidores de la enzima de conversion de angiotensina con acidos donadores de no, su procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la hipertension y otras enfermedades cardiovasculares.

Country Status (43)

Country Link
US (1) US7981920B2 (es)
EP (2) EP2039682B1 (es)
JP (1) JP4903187B2 (es)
KR (1) KR101070056B1 (es)
CN (1) CN101391973A (es)
AP (1) AP2010005204A0 (es)
AR (1) AR068488A1 (es)
AT (1) ATE476416T1 (es)
AU (1) AU2008217013B8 (es)
BR (1) BRPI0804073A2 (es)
CA (1) CA2639700C (es)
CL (1) CL2008002725A1 (es)
CR (1) CR11320A (es)
CY (1) CY1110782T1 (es)
DE (1) DE602008002027D1 (es)
DK (1) DK2039682T3 (es)
EA (1) EA015092B1 (es)
EC (1) ECSP10010040A (es)
ES (1) ES2349493T3 (es)
FR (1) FR2921365B1 (es)
GE (1) GEP20125479B (es)
HN (1) HN2010000533A (es)
HR (1) HRP20100545T1 (es)
JO (1) JO2664B1 (es)
MA (1) MA30320B1 (es)
MX (1) MX2008011954A (es)
MY (1) MY144927A (es)
NI (1) NI201000038A (es)
NZ (1) NZ572988A (es)
PA (1) PA8796701A1 (es)
PE (1) PE20091190A1 (es)
PL (1) PL2039682T3 (es)
PT (1) PT2039682E (es)
RS (1) RS51433B (es)
SA (1) SA08290599B1 (es)
SG (1) SG151200A1 (es)
SI (1) SI2039682T1 (es)
SV (1) SV2010003511A (es)
TN (1) TN2010000111A1 (es)
TW (1) TWI370118B (es)
UY (1) UY31339A1 (es)
WO (1) WO2009074733A2 (es)
ZA (1) ZA200808062B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
CN103848795B (zh) * 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
CA2340206A1 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti-pressor agents for vascular remodeling in genital dysfunction
DE10033580A1 (de) 2000-04-10 2001-10-11 Bayer Ag Verfahren zur Herstellung von Ditaurin und seinen Salzen
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
WO2005018561A2 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006078995A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
EP1877374A1 (en) * 2005-03-18 2008-01-16 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin converting enzyme inhibitors, compositions and methods of use
RU2271202C1 (ru) * 2005-05-04 2006-03-10 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
ATE485261T1 (de) * 2005-11-23 2010-11-15 Nicox Sa Salicylsäurederivate

Also Published As

Publication number Publication date
CY1110782T1 (el) 2015-06-10
CA2639700A1 (fr) 2009-03-21
EP2039682A1 (fr) 2009-03-25
UY31339A1 (es) 2008-10-31
TW200920352A (en) 2009-05-16
EA200801863A1 (ru) 2009-04-28
JO2664B1 (en) 2012-06-17
EA015092B1 (ru) 2011-06-30
AU2008217013B2 (en) 2012-08-16
JP2009137935A (ja) 2009-06-25
TN2010000111A1 (fr) 2011-09-26
ATE476416T1 (de) 2010-08-15
EP2039682B1 (fr) 2010-08-04
GEP20125479B (en) 2012-04-25
KR20090031298A (ko) 2009-03-25
PT2039682E (pt) 2010-09-27
US7981920B2 (en) 2011-07-19
HRP20100545T1 (hr) 2010-11-30
AU2008217013A8 (en) 2012-10-04
AU2008217013A1 (en) 2009-04-09
KR101070056B1 (ko) 2011-10-04
HN2010000533A (es) 2013-07-08
FR2921365A1 (fr) 2009-03-27
NI201000038A (es) 2010-07-15
MY144927A (en) 2011-11-30
BRPI0804073A2 (pt) 2009-06-16
SI2039682T1 (sl) 2010-10-29
FR2921365B1 (fr) 2012-10-12
CN101391973A (zh) 2009-03-25
DE602008002027D1 (de) 2010-09-16
ES2349493T3 (es) 2011-01-04
US20090082393A1 (en) 2009-03-26
AP2010005204A0 (en) 2010-04-30
PA8796701A1 (es) 2009-09-17
PE20091190A1 (es) 2009-08-09
ECSP10010040A (es) 2010-04-30
ZA200808062B (en) 2009-11-25
SA08290599B1 (ar) 2011-05-04
DK2039682T3 (da) 2010-11-08
MX2008011954A (es) 2009-03-20
AU2008217013B8 (en) 2012-10-04
PL2039682T3 (pl) 2010-10-29
CR11320A (es) 2010-06-29
CA2639700C (fr) 2012-08-28
WO2009074733A2 (fr) 2009-06-18
EP2236495A1 (fr) 2010-10-06
JP4903187B2 (ja) 2012-03-28
SV2010003511A (es) 2010-07-29
SG151200A1 (en) 2009-04-30
WO2009074733A3 (fr) 2009-08-20
NZ572988A (en) 2010-07-30
MA30320B1 (fr) 2009-04-01
RS51433B (en) 2011-04-30
CL2008002725A1 (es) 2009-06-12
TWI370118B (en) 2012-08-11

Similar Documents

Publication Publication Date Title
BR112014001018A2 (pt) derivado de azabenzimidazol tendo atividade de ativação de ampk
AR073136A1 (es) Compuestos de pirrol
UY30105A1 (es) Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas.
NI200900037A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.
BRPI1009212B8 (pt) Composto de piperazina capaz de inibir a prostaglandina d sintase, seus usos e composição farmacêutica
AR049401A1 (es) Aza-biciclononanos
PE20080524A1 (es) DERIVADOS DE 1H-IMIDAZO[4,5-b]PIRAZIN Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
CO6150179A2 (es) Derivados de n-(amino-heteroaril)-1h-hindol-2-carboxamidas su preparacion y su aplicacion en terapeutica
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR083743A1 (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones
AR070992A1 (es) Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1
BRPI1011683B8 (pt) derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos
AR068912A1 (es) Derivados de 6- aril/ heteroarilquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y utilizacion como inhibidores de cmet
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
BR112015016310A2 (pt) método para controlar peste artrópode
CO6341610A2 (es) Compuesto heterociclilo aromatico que contiene nitrogeno.
ECSP11011164A (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica
AR068488A1 (es) Sales de adicion de compuestos inhibidores de la enzima de conversion de angiotensina con acidos donadores de no, su procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la hipertension y otras enfermedades cardiovasculares.
CO6251285A2 (es) Derivado de tetrahidroisoquinolina novedoso
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
BR112014000594A2 (pt) composição para o controle de pragas artrópodes e método para controlar pragas artrópodes
DOP2011000296A (es) Compuesto de pirazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure